{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134793","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.079780+00:00","generated_at":"2026-06-02T06:40:05.392846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500","bullets":["Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.","Over 17,500 prescriptions dispensed launch-to-date (+361% vs last quarterly report); >3,800 prescribers.","SG&A expenses $62.0M (up from $18.6M YoY) reflecting commercial infrastructure build and marketing.","Cigna added VOQUEZNA to formularies; commercial coverage now ~48% of U.S. commercial lives (~72M covered).","FDA PDUFA date July 19, 2024 for NERD indication; Phase 3 NERD and Phase 2 EoE studies planned later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134793","json":"https://secwatch.observer/filing/0001193125-24-134793.json","markdown":"https://secwatch.observer/filing/0001193125-24-134793.md","text":"https://secwatch.observer/filing/0001193125-24-134793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/0001193125-24-134793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/d837391d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:40:05.392846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"835e7f8078acce5285ff176fdb63655506499140","claim":"Phathom Pharmaceuticals, Inc. reported the first quarter of 2024 results: revenue Net revenues for the first quarter 2024 were $1.9 million, net income Net loss for the first quarter 2024 was $82.9 million.","evidence_excerpt":"Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/0001193125-24-134793-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"Net revenues for the first quarter 2024 were $1.9 million"},{"label":"Net income","value":"Net loss for the first quarter 2024 was $82.9 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}